TrialsgrambetaRCTs are beautiful

RE-LY

2009

Randomized Evaluation of Long-term Anticoagulation Therapy

In 18,113 patients with non-valvular AF, dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin, with similar major bleeding.

Result

Efficacy: Stroke or systemic embolismRR 0.66

Below 1 favours dabigatran 150 mg twice daily, above 1 favours warfarin.

Event rates Dabigatran 150 mg twice daily 1.11% vs warfarin 1.69% per year

Also reported: 110 mg dose non-inferior with less bleed.

Original publication
Subtopic
Anticoagulation
Design
Open-label (PROBE), 2 yr
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Connolly SJ, et al. N Engl J Med. 2009;361(12):1139-1151.doi 10.1056/NEJMoa0905561

Discussion & critique

First NOAC win. Open-label design and dyspepsia signal. Renal clearance is dominant: avoid in CrCl < 30.

Discussed in podcasts